Telomir Pharmaceuticals, Inc. Common Stock(TELO)Earnings, Financials & Key Ratios
TELO•NASDAQ
$1.34
$46M mkt cap·Price updated May 6, 2026
AboutTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Show more
- Revenue$0
- EBITDA-$11M
- Net Income-$10M+37.0%
- EPS (Diluted)-0.33+41.1%
- ROE-317.65%+60.8%
TELO Key Insights
Telomir Pharmaceuticals, Inc. Common Stock (TELO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TELO Price & Volume
Telomir Pharmaceuticals, Inc. Common Stock (TELO) stock price & volume — 10-year historical chart
Loading chart...
TELO Growth Metrics
Telomir Pharmaceuticals, Inc. Common Stock (TELO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM37.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM41.55%
Return on Capital
10 Years-412.22%
5 Years-412.22%
3 Years-412.22%
Last Year-321.48%
TELO Peer Comparison
Telomir Pharmaceuticals, Inc. Common Stock (TELO) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TARA | 303.3M | 5.66 | -4.22 | -36.38% | 0.02 | |||
 ADTX | 69.91K | 0.14 | 0 | -79.23% | -7104.99% | -6.21% | 0.84 | |
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 LCTX | 347.66M | 1.43 | -5.11 | 53.24% | -436.47% | -134.53% | 0.06 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare TELO vs Peers
Telomir Pharmaceuticals, Inc. Common Stock (TELO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TELO Income Statement
Telomir Pharmaceuticals, Inc. Common Stock (TELO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 138.13K | 854.15K | 3.94M | 12.24M | 10.54M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 11.64K | 20.94K | 600.19K | 9.64M | 8.1M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 126.49K | 833.21K | 1.57M | 2.24M | 2.44M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 1.77M | 370.5K | 0 |
| Operating Income | -138.13K▲ 0% | -854.15K▼ 518.4% | -3.94M▼ 361.5% | -12.24M▼ 210.6% | -10.54M▲ 13.9% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -518.36% | -361.52% | -210.55% | 13.91% |
| EBITDA | 0 | 0 | -11.43M | 0 | -10.54M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | - | - | 100% | - |
| D&A (Non-Cash Add-back) | 138.13K | 854.15K | 0 | 12.24M | 0 |
| EBIT | -138.13K | -854.15K | -11.43M | -12.19M | -10.54M |
| Net Interest Income | 0 | 0 | -1.64M | 4.39M | 125.64K |
| Interest Income | 0 | 0 | 0 | 48K | 125.64K |
| Interest Expense | 0 | 0 | 1.64M | -4.34M | 0 |
| Other Income/Expense | 0 | 0 | -9.13M | -4.29M | 125.64K |
| Pretax Income | -138.13K▲ 0% | -854.15K▼ 518.4% | -13.07M▼ 1430.4% | -16.53M▼ 26.5% | -10.41M▲ 37.0% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -138.13K▲ 0% | -854.15K▼ 518.4% | -13.07M▼ 1430.4% | -16.53M▼ 26.5% | -10.41M▲ 37.0% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | -518.36% | -1430.4% | -26.48% | 37.01% |
| Net Income (Continuing) | -138.13K | -854.15K | -13.07M | -16.53M | -10.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.03▼ 512.8% | -0.44▼ 1427.8% | -0.56▼ 27.3% | -0.33▲ 41.1% |
| EPS Growth % | - | - | -1427.78% | -27.27% | 41.07% |
| EPS (Basic) | -0.00 | -0.03 | -0.44 | -0.56 | -0.33 |
| Diluted Shares Outstanding | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
| Basic Shares Outstanding | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
| Dividend Payout Ratio | - | - | - | - | - |
TELO Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock (TELO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 0 | 48.73K | 435.23K | 1.32M | 7.34M |
| Cash & Short-Term Investments | 0 | 1.42K | 1.23K | 1.27M | 7.29M |
| Cash Only | 0 | 1.42K | 1.23K | 1.27M | 7.29M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 130K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 47.31K | 303.28K | 0 | 54.69K |
| Total Non-Current Assets | 55K | 0 | 4.34M | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 55K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 4.34M | 0 | 0 |
| Total Assets | 55K▲ 0% | 48.73K▼ 11.4% | 4.77M▲ 9696.4% | 1.32M▼ 72.3% | 7.34M▲ 454.5% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | -11.4% | 9696.36% | -72.27% | 454.48% |
| Total Current Liabilities | 138.13K | 986.01K | 1.34M | 680.97K | 1.43M |
| Accounts Payable | 18.73K | 404.22K | 707.19K | 587.54K | 0 |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 581.79K | 101K | 93.43K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 119.4K | 0 | 527.38K | 0 | 1.43M |
| Current Ratio | - | 0.05x | 0.33x | 1.94x | 5.14x |
| Quick Ratio | - | 0.05x | 0.33x | 1.94x | 5.14x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 138.13K | 986.01K | 1.34M | 680.97K | 1.43M |
| Total Debt | 0 | 581.79K | 101K | 93.43K | 0 |
| Net Debt | 0 | 580.37K | 99.77K | -1.17M | -7.29M |
| Debt / Equity | - | - | 0.03x | 0.15x | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | -2.40x | - | - |
| Total Equity | -83.13K▲ 0% | -937.28K▼ 1027.5% | 3.44M▲ 466.8% | 643.04K▼ 81.3% | 5.91M▲ 819.6% |
| Equity Growth % | - | -1027.47% | 466.83% | -81.3% | 819.6% |
| Book Value per Share | -0.00 | -0.03 | 0.12 | 0.02 | 0.19 |
| Total Shareholders' Equity | -83.13K | -937.28K | 3.44M | 643.04K | 5.91M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -138.13K | -992.28K | -14.06M | -30.6M | -41.01M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
TELO Cash Flow Statement
Telomir Pharmaceuticals, Inc. Common Stock (TELO) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -119.4K | -468.66K | -3.86M | -5.07M | -3.69M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -292.53% | -723.58% | -31.37% | 27.26% |
| Net Income | -138.13K | -854.15K | -13.07M | -16.53M | -10.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 4.34M | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.87M | 5.29M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 9.1M | 130K | 840K |
| Working Capital Changes | 18.73K | 385.49K | 113.84K | 126.47K | 594.69K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 18.73K | 0 | 114.56K | 183.63K | -50.77K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 119.4K | 470.08K | 3.86M | 6.34M | 9.71M |
| Debt Issued (Net) | 0 | 462.39K | 3.17M | -101K | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 119.4K | 7.69K | -310.38K | -396.64K | 155.52K |
| Net Change in Cash | 0▲ 0% | 1.42K▲ 0% | -188▼ 113.2% | 1.26M▲ 672919.1% | 6.02M▲ 376.0% |
| Free Cash Flow | -119.4K▲ 0% | -468.66K▼ 292.5% | -3.86M▼ 723.6% | -5.07M▼ 31.4% | -3.69M▲ 27.3% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -292.51% | -723.58% | -31.36% | 27.26% |
| FCF per Share | -0.00 | -0.02 | -0.13 | -0.17 | -0.12 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.55x | 0.30x | 0.31x | 0.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
TELO Key Ratios
Telomir Pharmaceuticals, Inc. Common Stock (TELO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -1045.36% | -810.18% | -317.65% |
| Return on Invested Capital (ROIC) | - | - | -185.88% | -610.42% | - |
| Debt / Equity | - | - | 0.03x | 0.15x | - |
| Interest Coverage | - | - | -2.40x | - | - |
| FCF Conversion | 0.86x | 0.55x | 0.30x | 0.31x | 0.35x |
TELO Frequently Asked Questions
Telomir Pharmaceuticals, Inc. Common Stock (TELO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Telomir Pharmaceuticals, Inc. Common Stock (TELO) grew revenue by 0.0% over the past year. Growth has been modest.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported a net loss of $10.4M for fiscal year 2025.
Dividend & Returns
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a return on equity (ROE) of -317.6%. Negative ROE indicates the company is unprofitable.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) had negative free cash flow of $3.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More TELO
Telomir Pharmaceuticals, Inc. Common Stock (TELO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates